Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma

Jay P. Reddy; Mike Hernandez; Jillian R. Gunther; Bouthaina S. Dabaja; Geoffrey V. Martin; Wen Jiang; Mani Akhtari; Pamela K. Allen; Bradley J. Atkinson; Grace L. Smith; Chelsea C. Pinnix; Sarah A. Milgrom; Zeinab Abou Yehia; Eleanor M. Osborne; Yasuhiro Oki; Hun Lee; Fredrick Hagemeister; Michelle A. Fanale

doi:10.1111/bjh.15054

Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma

Jay P. Reddy, Mike Hernandez, Jillian R. Gunther, Bouthaina S. Dabaja, Geoffrey V. Martin, Wen Jiang, Mani Akhtari, Pamela K. Allen, Bradley J. Atkinson, Grace L. Smith, Chelsea C. Pinnix, Sarah A. Milgrom, Zeinab Abou Yehia, Eleanor M. Osborne, Yasuhiro Oki, Hun Lee, Fredrick Hagemeister, Michelle A. Fanale

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2-year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).

Original language	English (US)
Pages (from-to)	545-549
Number of pages	5
Journal	British Journal of Haematology
Volume	180
Issue number	4
DOIs	https://doi.org/10.1111/bjh.15054
State	Published - Feb 1 2018
Externally published	Yes

Keywords

Hodgkin lymphoma
lymphocyte
neutrophil
platelet
refractory
relapse

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.15054

Cite this

Reddy, J. P., Hernandez, M., Gunther, J. R., Dabaja, B. S., Martin, G. V., Jiang, W., Akhtari, M., Allen, P. K., Atkinson, B. J., Smith, G. L., Pinnix, C. C., Milgrom, S. A., Abou Yehia, Z., Osborne, E. M., Oki, Y., Lee, H., Hagemeister, F., & Fanale, M. A. (2018). Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. British Journal of Haematology, 180(4), 545-549. https://doi.org/10.1111/bjh.15054

Reddy, JP, Hernandez, M, Gunther, JR, Dabaja, BS, Martin, GV, Jiang, W, Akhtari, M, Allen, PK, Atkinson, BJ, Smith, GL, Pinnix, CC, Milgrom, SA, Abou Yehia, Z, Osborne, EM, Oki, Y, Lee, H, Hagemeister, F & Fanale, MA 2018, 'Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma', British Journal of Haematology, vol. 180, no. 4, pp. 545-549. https://doi.org/10.1111/bjh.15054

@article{5a7d8cbd8b38473fa0cad2d1ec448f1a,

title = "Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma",

abstract = "To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2-year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).",

keywords = "Hodgkin lymphoma, lymphocyte, neutrophil, platelet, refractory, relapse",

author = "Reddy, {Jay P.} and Mike Hernandez and Gunther, {Jillian R.} and Dabaja, {Bouthaina S.} and Martin, {Geoffrey V.} and Wen Jiang and Mani Akhtari and Allen, {Pamela K.} and Atkinson, {Bradley J.} and Smith, {Grace L.} and Pinnix, {Chelsea C.} and Milgrom, {Sarah A.} and {Abou Yehia}, Zeinab and Osborne, {Eleanor M.} and Yasuhiro Oki and Hun Lee and Fredrick Hagemeister and Fanale, {Michelle A.}",

year = "2018",

month = feb,

day = "1",

doi = "10.1111/bjh.15054",

language = "English (US)",

volume = "180",

pages = "545--549",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma

AU - Reddy, Jay P.

AU - Hernandez, Mike

AU - Gunther, Jillian R.

AU - Dabaja, Bouthaina S.

AU - Martin, Geoffrey V.

AU - Jiang, Wen

AU - Akhtari, Mani

AU - Allen, Pamela K.

AU - Atkinson, Bradley J.

AU - Smith, Grace L.

AU - Pinnix, Chelsea C.

AU - Milgrom, Sarah A.

AU - Abou Yehia, Zeinab

AU - Osborne, Eleanor M.

AU - Oki, Yasuhiro

AU - Lee, Hun

AU - Hagemeister, Fredrick

AU - Fanale, Michelle A.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2-year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).

AB - To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2-year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).

KW - Hodgkin lymphoma

KW - lymphocyte

KW - neutrophil

KW - platelet

KW - refractory

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=85038864650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038864650&partnerID=8YFLogxK

U2 - 10.1111/bjh.15054

DO - 10.1111/bjh.15054

M3 - Article

C2 - 29271057

AN - SCOPUS:85038864650

SN - 0007-1048

VL - 180

SP - 545

EP - 549

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this